NCT00718341View on ClinicalTrials.gov

Efficacy, Safety and Tolerability of AFQ056 in Fragile X Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

February 28, 2009

Conditions
Fragile X Syndrome
Interventions
DRUG

AF056

DRUG

Placebo

Trial Locations (3)

1011

Novartis Investigator Site, Lausanne

69677

Novartis Investigator Site, Bron

00168

Novartis Investigator Site, Rome

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00718341 - Efficacy, Safety and Tolerability of AFQ056 in Fragile X Patients | Biotech Hunter | Biotech Hunter